|
See related Zyprexa information |
|
|
|
Manufacturer |
Eli Lilly |
|
Distributor |
DKSH |
|
Contents |
Olanzapine |
|
Indications |
Tab/Orodispersible tab Acute & maintenance treatment of schizophrenia & other psychoses where positive &/or negative symptoms are prominent. Alleviate secondary affective symptoms commonly associated w/ schizophrenia & related disorders. Treatment of acute manic or mixed episodes in bipolar disorders, w/ or w/o psychotic features & w/ or w/o a rapid cycling course. Treatment of moderate or severe manic episode. Prevention of recurrence in patients w/ bipolar disorder. Vial Rapid control of agitation & disturbed behaviours in patients w/ schizophrenia & bipolar disorder, when oral therapy is not appropriate.
Click to view Zyprexa detailed prescribing infomation |
|
Dosage |
Acute & maintenance treatment of schizophrenia & other psychoses Initially 10 mg once daily. Dose range: 5-20 mg/day. Acute manic or mixed episodes in bipolar disorders Initially 10-15 mg once daily. Moderate or severe manic episode Initially 15 mg as single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence of manic, mixed or depressive episodes in bipolar I disorder Initially 10 mg once daily. Dose range: 5-20 mg/day. Vial Initially 10 mg as a single IM inj. If needed, a 2nd inj of 5-10 mg is given 2 hr after the 1st inj. Max (including oral olanzapine): 20 mg/day w/ not >3 inj in any 24-hr period.
Click to view Zyprexa detailed prescribing infomation |
|
Overdosage |
View Zyprexa overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Place orodispersible tab in mouth; it will dissolve rapidly & may be swallowed w/ or w/o water. It may also be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration.). |
|
Contraindications |
Patient at risk for narrow-angle glaucoma.
Click to view Zyprexa detailed prescribing infomation |
|
Special Precautions |
Hyperglycemia or exacerbation of preexisting diabetes, ketoacidosis, diabetic coma; transient, asymptomatic elevations of hepatic transaminases; low leukocyte &/or neutrophil counts; history of drug-induced bone marrow depression/toxicity due to concomitant illness, radiation or chemotherapy; hypereosinophilic conditions or myeloproliferative disease; neuroleptic malignant syndrome (NMS), seizures, tardive dyskinesia, postural hypotension, prostatic hypertrophy, paralytic ileus & related conditions. Dopamine agonist-associated psychosis in patients w/ Parkinson's disease. Dementia-related psychosis in elderly &/or behavioural disturbances. Monitor BP, pulse, resp rate & level of consciousness during IM administration. Gradual dose reduction if to be discontinued. Phenylketonuria (Zyprexa Zydis contains aspartame). Pregnancy & lactation. May affect ability to drive or operate machinery.
Click to view Zyprexa detailed prescribing infomation |
|
Adverse Drug Reactions |
Somnolence, wt gain, abnormal gait, dizziness, asthenia, increased appetite, peripheral edema, orthostatic hypotension, lipid alteration, mild transient anticholinergic effects eg constipation & dry mouth, urticaria, contact dermatitis, increased plasma glucose & prolactin level, elevation of hepatic transaminases. Cerebrovascular adverse events in elderly eg stroke & transient ischemic attack. Vial: Inj site discomfort, postural hypotension, bradycardia w/ or w/o hypotension or syncope, tachycardia.
View ADR Monitoring Form |
|
Drug Interactions |
Activated charcoal, smoking, carbamazepine, alcohol, fluvoxamine, dopamine agonists, ciprofloxacin. Agents that induce hypotension, bradycardia, resp & CNS depression. Drugs that increase QTc interval.
View more drug interactions with Zyprexa |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Zyprexa storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Zyprexa description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Zyprexa mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
